Uncategorized

Saphnelo™ Approved as Self-Administered Autoinjector

|

The U.S. Food and Drug Administration just granted approval for a self-administered, once-weekly autoinjector of Saphenlo (anifrolumab), for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.  The decision was based on TULIP-SC Phase 3 trial results, which showed a statistically significant and clinically meaningful reduction in disease activity for participants with moderate to severe … Saphnelo™ Approved as Self-Administered Autoinjector

Lupus & Life: Heart Health, Lupus, and How You Can Take Control

|

How does lupus impact heart health?  People living with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular disease, with even greater risk among those with lupus nephritis. Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, convened leading rheumatologists and people living with lupus for the first in our webinar series, “Lupus & Life: Science, Support, and Self-Care,” to take a closer look at … Lupus & Life: Heart Health, Lupus, and How You Can Take Control

FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE

|

The U.S. Food and Drug Administration has accepted the supplemental Biologics License Application from Genentech for Gazyva® (obinutuzumab) to treat systemic lupus erythematosus (SLE), the most common form of lupus. The acceptance is based on Phase 3 data showing that Gazyva significantly reduced disease activity and less reliance on steroids in people with SLE.   According to results published in the New England Journal of Medicine and presented at SLEuro 2026, more than 75% of people treated with Gazyva plus standard therapy achieved … FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE

New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus 

|

Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the investigational litifilimab in development by Biogen significantly reduced skin disease activity in cutaneous lupus erythematosus (CLE). These data were presented at the American Academy of Dermatology Annual Meeting on … New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus 

Stay Well with Lupus: Tips for Meditation, Movement, and Stress Management 

|

Living with lupus means managing physical symptoms, emotional ups and downs, and the everyday challenges that come with an autoimmune condition. While there’s no one‑size‑fits‑all approach, many people find that caring for both the mind and body can make a meaningful difference.  To help support the lupus community, Lupus Therapeutics, the clinical affiliate of the Lupus … Stay Well with Lupus: Tips for Meditation, Movement, and Stress Management 

New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

|

A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease activity and lowered steroid use in people with systemic lupus erythematosus (SLE), the most common form of lupus. The results were also presented today at the 15th European Lupus Society meeting, SLEuro 2026.  More than 75% of people treated with Gazyva plus standard therapy achieved at least … New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

Turning the Tide in Lupus Treatment: Clinical Trials as Standard of Care

|

People living with lupus can have early access to innovative therapies alongside personalized support from a broader care team. How? Through participation in clinical trials.  Historically, clinical trial participation for lupus was discussed only after standard treatments failed the patient. Now, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, is working to make … Turning the Tide in Lupus Treatment: Clinical Trials as Standard of Care

Lupus Clinical Research: A New Wave of Innovation 

|

A wave of lupus clinical research advances has been building over the past decade.  Now, it is reaching a crest.  A 2025 pipeline report identifies over 140 lupus therapies from 120+ companies now in clinical trials.i This surge of innovation is translating into potential treatments that are targeted, safer, and showing potential effectiveness for people living with lupus—offering more choices and options for treating the disease.  “This is … Lupus Clinical Research: A New Wave of Innovation 

Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

|

New York, N.Y., October 21, 2025 —  With lupus research accelerating at an unprecedented pace, the Lupus Research Alliance heads to ACR Convergence 2025 (October 24-29, Chicago), the annual meeting of the American College of Rheumatology, to demonstrate how its unique impact across the full research continuum is shaping the next generation of treatments and research.  As the … Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative

|
Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative.

Imagine a future where everyday choices – like what people eat – could shape how lupus is treated and managed. That future may be closer than ever.   Earlier this year, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, launched a pioneering initiative: Investigate Dietary Approaches for Lupus (IDEAL). It is the first-ever program … Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative

An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie J. Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance 

|
Can diet make a difference in lupus?

Could diet and gut health impact the lived experience of lupus? This intriguing question lies at the heart of a groundbreaking initiative by Lupus Therapeutics (LT), the clinical research affiliate of the Lupus Research Alliance (LRA), called IDEAL (Investigate Dietary Approaches for Lupus). IDEAL will provide up to two grants for pilot clinical studies evaluating … An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie J. Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance 

FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

|
Breaking news: Gazyva for Lupus Nephritis

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. The acceptance is based on results from the Phase 3 REGENCY study showing improved complete renal … FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®